From Name:
From Email:
To Name:
To Email:

Optional Message:

SURTAVI Results Confirmed: TAVR Similar to Surgery in Intermediate-risk Patients

from Healio

A final analysis of 24-month results from the SURTAVI trial confirmed interim findings that transcatheter aortic valve replacement (AVR) with a self-expanding bioprosthesis had similar outcomes versus surgical AVR in patients at intermediate risk for surgery. As Cardiology Today’s Intervention previously reported, in the interim 24-month analysis published in March 2017, patients who had TAVR with a self-expanding valve (CoreValve or Evolut R, Medtronic) had similar rates of death or disabling stroke as patients who underwent surgery. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063